title: Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes.
abstract: Transporters responsible for hepatic uptake and biliary clearance (CLBile) of rosuvastatin (RSV) have been well characterized. However, the contribution of basolateral efflux clearance (CLBL) to hepatic and systemic exposure of RSV is unknown. Additionally, the appropriate design of in vitro hepatocyte efflux experiments to estimate CLBile versus CLBL remains to be established. A novel uptake and efflux protocol was developed in sandwich-cultured hepatocytes (SCH) to achieve desired tight junction modulation while maintaining cell viability. Subsequently, studies were conducted to determine the role of CLBL in the hepatic disposition of RSV using SCH from wild-type (WT) and multidrug resistance-associated protein 2 (Mrp2)-deficient (TR(-)) rats in the absence and presence of the P-glycoprotein and breast cancer resistance protein (Bcrp) inhibitor elacridar (GF120918). RSV CLBile was nearly ablated by GF120918 in TR(-) SCH, confirming that Mrp2 and Bcrp are responsible for the majority of RSV CLBile. Pharmacokinetic modeling revealed that CLBL and CLBile represent alternative elimination routes with quantitatively similar contributions to the overall hepatocellular excretion of RSV in rat SCH under baseline conditions (WT SCH in the absence of GF120918) and also in human SCH. Membrane vesicle experiments revealed that RSV is a substrate of MRP4 (Km = 21 ± 7 µM, Vmax = 1140 ± 210 pmol/min per milligram of protein). Alterations in MRP4-mediated RSV CLBL due to drug-drug interactions, genetic polymorphisms, or disease states may lead to changes in hepatic and systemic exposure of RSV, with implications for the safety and efficacy of this commonly used medication.
authors.affiliation: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
authors.forename: Nathan D
authors.initials: ND
authors.lastname: Pfeifer
authors.forename: Kyunghee
authors.initials: K
authors.lastname: Yang
authors.forename: Kim L R
authors.initials: KL
authors.lastname: Brouwer
mesh_terms: D000166:Acridines / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000502:physiology; D000465:Algorithms; D000818:Animals; D001646:Bile / Q000378:metabolism*; D002352:Carrier Proteins / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D002478:Cells, Cultured; D005464:Fluorobenzenes / Q000493:pharmacokinetics*; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000493:pharmacokinetics*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D008954:Models, Biological; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000378:metabolism; D010957:Plasmids; D011743:Pyrimidines / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000493:pharmacokinetics*; D044005:Tetrahydroisoquinolines / Q000494:pharmacology; D019108:Tight Junctions / Q000378:metabolism
chemical_list: D000166:Acridines; D000255:Adenosine Triphosphate; D002352:Carrier Proteins; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007770:L-Lactate Dehydrogenase; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D011743:Pyrimidines; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides; D044005:Tetrahydroisoquinolines; C489542:Abcc4 protein, rat; C114462:multidrug resistance-associated protein 3; C083501:Elacridar
references.citation: Anal Chem. 2009 Mar 15;81(6):2251-9
references.pmid: 19209887
references.citation: J Pharmacol Exp Ther. 2010 Jan;332(1):26-34
references.pmid: 19801447
references.citation: Drug Metab Dispos. 2012 Jan;40(1):93-103
references.pmid: 21979928
references.citation: Gastroenterology. 2006 May;130(6):1793-806
references.pmid: 16697742
references.citation: Clin Pharmacol Ther. 2010 May;87(5):558-62
references.pmid: 20130569
references.citation: Semin Liver Dis. 1988 Nov;8(4):308-16
references.pmid: 2850606
references.citation: Mol Pharmacol. 2001 May;59(5):1171-80
references.pmid: 11306701
references.citation: Xenobiotica. 2012 Apr;42(4):327-38
references.pmid: 22035568
references.citation: Hepatology. 1998 Aug;28(2):286-95
references.pmid: 9695989
references.citation: Xenobiotica. 2003 Apr;33(4):379-88
references.pmid: 12745873
references.citation: Pharm Res. 2010 Sep;27(9):1987-98
references.pmid: 20652625
references.citation: Drug Metab Dispos. 2012 May;40(5):1007-17
references.pmid: 22344703
references.citation: Clin Pharmacol Ther. 2009 Aug;86(2):197-203
references.pmid: 19474787
references.citation: Mol Pharm. 2010 Jun 7;7(3):630-41
references.pmid: 20438085
references.citation: JAMA. 2003 Apr 2;289(13):1681-90
references.pmid: 12672737
references.citation: J Biol Chem. 2001 Dec 7;276(49):46400-7
references.pmid: 11581266
references.citation: Drug Metab Dispos. 2012 Jan;40(1):83-92
references.pmid: 21994437
references.citation: Drug Metab Dispos. 2008 Oct;36(10):2014-23
references.pmid: 18617601
references.citation: Drug Metab Rev. 2010 Aug;42(3):446-71
references.pmid: 20109035
references.citation: Clin Pharmacol Ther. 2004 Aug;76(2):167-77
references.pmid: 15289793
references.citation: Med J Aust. 2001 Nov 5;175(9):486-9
references.pmid: 11758079
references.citation: Lab Invest. 2002 Feb;82(2):193-201
references.pmid: 11850532
references.citation: J Hepatol. 2004 Apr;40(4):585-91
references.pmid: 15030973
references.citation: Clin Chim Acta. 2006 Nov;373(1-2):99-103
references.pmid: 16784736
references.citation: Drug Metab Dispos. 2011 Sep;39(9):1503-10
references.pmid: 21673128
references.citation: Toxicol In Vitro. 2010 Mar;24(2):605-10
references.pmid: 19853032
references.citation: Drug Metab Dispos. 2006 May;34(5):738-42
references.pmid: 16415124
references.citation: Clin Pharmacol Ther. 2004 May;75(5):455-63
references.pmid: 15116058
references.citation: Drug Metab Dispos. 2005 Feb;33(2):287-93
references.pmid: 15528320
references.citation: Br J Clin Pharmacol. 2003 Jan;55(1):94-9
references.pmid: 12534645
references.citation: Hepatology. 2012 May;55(5):1485-94
references.pmid: 22105759
references.citation: Eur J Clin Pharmacol. 2003 Feb;58(10):669-75
references.pmid: 12610743
references.citation: Pharmacogenomics J. 2008 Feb;8(1):42-52
references.pmid: 17404579
references.citation: Drug Metab Dispos. 2009 Jan;37(1):66-73
references.pmid: 18832477
references.citation: Drug Metab Dispos. 2006 Apr;34(4):556-62
references.pmid: 16204465
references.citation: Biochem J. 2003 Apr 15;371(Pt 2):361-7
references.pmid: 12523936
references.citation: J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):570-8
references.pmid: 18176327
references.citation: Xenobiotica. 2002 Aug;32(8):715-27
references.pmid: 12296991
references.citation: Drug Metab Dispos. 2011 Dec;39(12):2387-94
references.pmid: 21865320
references.citation: Pharm Res. 2008 Aug;25(8):1851-60
references.pmid: 18509604
references.citation: J Pharmacol Exp Ther. 2008 Sep;326(3):983-90
references.pmid: 18574002
references.citation: J Pharmacol Exp Ther. 1999 Jun;289(3):1592-9
references.pmid: 10336557
references.citation: Clin Ther. 2003 Oct;25(10):2553-63
references.pmid: 14667956